Wellington Management Group LLP trimmed its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) by 8.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 13,640,416 shares of the company’s stock after selling 1,202,560 shares during the period. Wellington Management Group LLP owned about 1.69% of Roivant Sciences worth $153,182,000 at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of ROIV. Charles Schwab Investment Management Inc. increased its holdings in Roivant Sciences by 207.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,923,879 shares of the company’s stock valued at $22,471,000 after acquiring an additional 1,297,134 shares in the last quarter. Citigroup Inc. increased its stake in shares of Roivant Sciences by 45.6% during the 3rd quarter. Citigroup Inc. now owns 326,431 shares of the company’s stock worth $3,813,000 after purchasing an additional 102,279 shares in the last quarter. Rhumbline Advisers raised its position in shares of Roivant Sciences by 35.7% during the 3rd quarter. Rhumbline Advisers now owns 407,351 shares of the company’s stock worth $4,758,000 after purchasing an additional 107,251 shares during the last quarter. Invesco Ltd. lifted its stake in Roivant Sciences by 3.6% in the 3rd quarter. Invesco Ltd. now owns 1,379,985 shares of the company’s stock valued at $16,118,000 after buying an additional 47,547 shares in the last quarter. Finally, Algert Global LLC acquired a new stake in Roivant Sciences during the 3rd quarter valued at $1,313,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.
Roivant Sciences Trading Up 1.1 %
ROIV stock opened at $10.84 on Thursday. Roivant Sciences Ltd. has a 52 week low of $8.24 and a 52 week high of $13.24. The company has a market cap of $8.01 billion, a price-to-earnings ratio of 2.14 and a beta of 1.25. The company has a quick ratio of 25.24, a current ratio of 25.24 and a debt-to-equity ratio of 0.07. The business has a fifty day simple moving average of $10.94 and a 200-day simple moving average of $10.85.
Analyst Upgrades and Downgrades
Read Our Latest Report on ROIV
Roivant Sciences Profile
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
See Also
- Five stocks we like better than Roivant Sciences
- What is a buyback in stocks? A comprehensive guide for investors
- Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside
- How to Calculate Inflation Rate
- Campbell Soup Co. Targets Fiscal Q4 Stock Recovery
- What Do S&P 500 Stocks Tell Investors About the Market?
- Zebra Analysts Upgrade Stock, Forecasting Major Reversal
Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report).
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.